EUVIMEDEUVIMED entdecken
Crossref

Single-center Evaluation of Safety & Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Solid Organ Transplantation

Helen Sweiss iD, Reed Hall, Dominik Zeilmann, Jesus Escamilla, Suverta Bhayana, Rupal Patel, Christina Long

Progress in Transplantation · 2022-12 · 32 (4) · 357-362

DOI: 10.1177/15269248221122867 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Progress in Transplantation, online erschienen am 29.08.2022. Verfasst von Helen Sweiss und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapy & Pharmacy Services, 43159University Health System, 4502 Medical Drive, San Antonio, 78229 TX, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Organ Transplantation. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Given the negative outcomes associated with uncontrolled diabetes mellitus, non-insulin therapies with glycemic, cardiovascular, and weight-loss benefits in the general population, such as the glucagonlike peptide-1 receptor agonists (GLP1-RA) have become a more alluring therapeutic option in transplant populations. However, limited evidence exists to demonstrate its safety and efficacy in solid organ transplant.

Methods

This program evaluation included adult kidney, liver, lung transplant recipients initiated on a GLP1-RA for diabetes mellitus management for a minimum of 3 months, had at least one follow-up visit after starting therapy, and had at least one hemoglobin A1c (HbA1c) level drawn between 3–12 months after GLP1-RA initiation. Outcomes were assessed at time of initiation of GLP1-RA (baseline) and 3–12 months post-initiation. Nadir values between 3–12 months were utilized to assess outcomes.

Results

One-hundred eighteen patients met study inclusion criteria. Seventy-percent of patients received a kidney transplant, 19.5% received a liver transplant, and 6.8% received a lung transplant. A statistically significant difference was observed in median fasting blood glucose and HbA1c at baseline to 3–12-month nadir (P < 0.0001). A significant weight loss benefit was also observed. The rate of adverse drug reactions was low. Seven-percent of patients experienced nausea, 4.2% developed pancreatitis, and 7.1% reported having had at least one hypoglycemic event.

Discussion

This is the largest study evaluating GLP1-RA in organ transplantation and demonstrates GLP1-RA is both safe and effective. Further assessment on long-term use of these agents on cardiovascular and renal outcomes is still needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Organ TransplantationAdultHumansGlycated HemoglobinGlucagon-Like Peptide-1 ReceptorHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

clinical outcomesdiabetesdiabetes therapyendocrinologygeneralpharmacologypost-transplanttype 2weight loss

Substanzen

Glycated HemoglobinGlucagon-Like Peptide-1 ReceptorHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Pharmacotherapy & Pharmacy Services, 43159University Health System, 4502 Medical Drive, San Antonio, 78229 TX, USA.
  • University Health Transplant Institute, 43159University Health System, 4502 Medical Drive, San Antonio, 78229 TX, USA.
  • Pharmacotherapy Education and Research Center, 14742The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, 78229 TX, USA.
  • Pharmacotherapy Division, 15528The University of Texas at Austin, College of Pharmacy, 2409 University Avenue, Austin, 78712 TX, USA.
  • 130378The University of Incarnate Word, Feik School of Pharmacy, 703 E Hildebrand Avenue, San Antonio, 78212 TX, USA.
  • Department of Nephrology, 14742The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, 78229 TX, USA.

ORCID-Profile: Helen Sweiss

Zitieren

APA

Sweiss, H., Hall, R., Zeilmann, D., Escamilla, J., Bhayana, S., Patel, R., & Long, C. (2022). Single-center Evaluation of Safety & Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Solid Organ Transplantation. Progress in Transplantation, 32(4), 357-362. https://doi.org/10.1177/15269248221122867

Vancouver

Sweiss H, Hall R, Zeilmann D, Escamilla J, Bhayana S, Patel R, et al. Single-center Evaluation of Safety & Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Solid Organ Transplantation. Progress in Transplantation. 2022;32(4):357-362. doi:10.1177/15269248221122867

BibTeX
@article{Sweiss2022,
  author = {Sweiss, Helen and Hall, Reed and Zeilmann, Dominik and Escamilla, Jesus and Bhayana, Suverta and Patel, Rupal and Long, Christina},
  title = {Single-center Evaluation of Safety & Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Solid Organ Transplantation},
  journal = {Progress in Transplantation},
  year = {2022},
  volume = {32},
  number = {4},
  pages = {357--362},
  doi = {10.1177/15269248221122867}
}
Kostenlos starten →